Back to top
more

Altimmune (ALT)

(Real Time Quote from BATS)

$7.24 USD

7.24
650,573

+0.04 (0.56%)

Updated Apr 26, 2024 12:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Altimmune (ALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Altimmune's (ALT) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the development of its lead pipeline candidate, pemvidutide.

Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study

by Zacks Equity Research

Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.

Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study

by Zacks Equity Research

Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023. The stock rises 7%.

Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval

by Zacks Equity Research

Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.

Altimmune (ALT) Stock Down Despite Positive Obesity Study Data

by Zacks Equity Research

Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate.

Zoetis' (ZTS) Q4 Earnings in Line With Estimates, Revenues Beat

by Zacks Equity Research

Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.

Teladoc (TDOC) to Reduce Operating Costs, Shares Fall 6.6%

by Zacks Equity Research

Teladoc (TDOC) is likely to book a $17-million charge in 2023, of which, around $10 million will come from staff reduction moves.

Why You Should Keep Acadia Healthcare (ACHC) in Your Portfolio

by Zacks Equity Research

The constant growth in the senior population is expected to be beneficial for companies like Acadia Healthcare (ACHC) as demand for hospital services rises.

Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe

by Zacks Equity Research

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

Altimmune, Inc. (ALT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.04% and 99.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Altimmune's (ALT) Data From NASH Study Fail to Impress Investors

by Zacks Equity Research

Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.

Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 6.67% and 99.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Altimmune, Inc. (ALT) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Altimmune, Inc. (ALT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.

Molina Healthcare (MOH) to Buy My Choice Wisconsin for $150M

by Zacks Equity Research

Molina Healthcare (MOH) expects the buyout to complement its existing Medicaid business in Wisconsin.

Encompass Health (EHC) to Build New Rehab Unit in Missouri

by Zacks Equity Research

Encompass Health (EHC) and BJC HealthCare's new rehabilitation hospital is expected to come online in 2024.

Teladoc (TDOC) Widens Primary360 Offerings With New Services

by Zacks Equity Research

Teladoc (TDOC) will provide in-home and on-demand phlebotomy services for its Primary360 members with Scarlet Health's support.

Why You Should Hold Elevance Health (ELV) in Your Portfolio

by Zacks Equity Research

Elevance Health (ELV) continues witnessing a rise in the usage of its virtual care services, which is a vital driver.

Why Pediatrix Medical (MD) is a Solid Bet for Your Portfolio

by Zacks Equity Research

Pediatrix Medical (MD) is expected to boost its services across maternal-fetal medicine, neonatology and obstetrics, plus 18 pediatric subspecialty offerings.

Here's Why Select Medical (SEM) Stock is a Strong Buy Now

by Zacks Equity Research

Strategic alliances are bolstering Select Medical's (SEM) growth potential while mitigating the risk factor.

Universal Health (UHS) Cuts Guidance, Falls 6.1%: What's Ahead?

by Zacks Equity Research

Universal Health's (UHS) acute care hospitals experience lower-than-expected patient volumes in the second quarter, inducing a decline in revenues and profits.

Is Altimmune (ALT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Altimmune, Inc. (ALT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.

Select Medical (SEM), Inova Health Form JV in Northern Virginia

by Zacks Equity Research

The JV between Select Medical (SEM) and Inova Health System is expected to own and operate a new 32-bed critical illness recovery facility.

Why You Should Retain Humana (HUM) in Your Portfolio Now

by Zacks Equity Research

Humana's (HUM) strategic acquisitions help it boost its footprint and expand the product portfolio.